Pacira BioSciences Inc (NASDAQ: PCRX) kicked off on Tuesday, down -3.14% from the previous trading day, before settling in for the closing price of $24.85. Over the past 52 weeks, PCRX has traded in a range of $11.16-$31.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 11.26%. While this was happening, its average annual earnings per share was recorded -9.64%. With a float of $44.24 million, this company’s outstanding shares have now reached $46.24 million.
The extent of productivity of a business whose workforce counts for 790 workers is very important to gauge. In terms of profitability, gross margin is 71.6%, operating margin of -9.81%, and the pretax margin is -9.0%.
Pacira BioSciences Inc (PCRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Pacira BioSciences Inc is 4.39%, while institutional ownership is 111.26%. The most recent insider transaction that took place on Mar 06 ’25, was worth 11,625. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Medical Officer sold 879 for $18.40, making the entire transaction worth $16,174. This insider now owns 93,444 shares in total.
Pacira BioSciences Inc (PCRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.75 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.94% during the next five years compared to -51.99% drop over the previous five years of trading.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
Take a look at Pacira BioSciences Inc’s (PCRX) current performance indicators. Last quarter, stock had a quick ratio of 2.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.59. Likewise, its price to free cash flow for the trailing twelve months is 6.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.20, a number that is poised to hit 0.59 in the next quarter and is forecasted to reach 3.72 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
The latest stats from [Pacira BioSciences Inc, PCRX] show that its last 5-days average volume of 0.78 million was inferior to 0.86 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 49.98%. Additionally, its Average True Range was 1.02.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 69.63%, which indicates a significant increase from 52.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.63% in the past 14 days, which was lower than the 47.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.79, while its 200-day Moving Average is $19.94. Now, the first resistance to watch is $24.61. This is followed by the second major resistance level at $25.15. The third major resistance level sits at $25.46. If the price goes on to break the first support level at $23.76, it is likely to go to the next support level at $23.45. Assuming the price breaks the second support level, the third support level stands at $22.91.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
The company with the Market Capitalisation of 1.11 billion has total of 46,276K Shares Outstanding. Its annual sales at the moment are 700,970 K in contrast with the sum of -99,560 K annual income. Company’s last quarter sales were recorded 187,250 K and last quarter income was 16,040 K.
